Definitive surgery of primary lesion should be prioritized over preoperative chemotherapy to treat high-grade osteosarcoma in patients aged 41-65 years

被引:12
|
作者
Hayakawa, Keiko [1 ]
Matsumoto, Seiichi [1 ]
Ae, Keisuke [1 ]
Tanizawa, Taisuke [1 ]
Funauchi, Yuki [1 ]
Minami, Yusuke [1 ]
Saito, Masanori [1 ]
Okawa, Atsushi [2 ]
机构
[1] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Orthoped Oncol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan
[2] Tokyo Med & Dent Univ, Dept Orthoped Surg, Tokyo, Japan
关键词
Osteosarcoma; Definitive surgery; Patient aged 41-65 years; NEOADJUVANT CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; NONMETASTATIC OSTEOSARCOMA; OSTEOGENIC-SARCOMA; PHASE-II; OLDER; IFOSFAMIDE; BONE; EXTREMITIES; DOXORUBICIN;
D O I
10.1186/s10195-020-00552-w
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background Recently, the number of osteosarcomas in middle-aged and older patients has demonstrated an increasing trend; moreover, their results are comparatively worse than those of young patients. In Europe and the USA, the prognosis for osteosarcoma in middle-aged and older patients has improved with adjuvant chemotherapy. In Japan, however, the prognosis has remained poor. Materials and Methods We retrospectively analyzed the outcomes of osteosarcoma, especially in regards to preoperative chemotherapy, from January 1980 to July 2014. A total of 29 patients with high-grade osteosarcoma between the age of 40 and 65 years were included. We included patients without distant metastasis and with primary lesions that were deemed resectable. The mean age was 52.8 years (range 41-65 years), and the mean follow-up period was 103.2 months (range 5-314 months). Results Adjuvant chemotherapy was administered to 27 of 29 patients (93%), and 8 of 15 cases (53%) were able to undergo preoperative chemotherapy as planned, including CDDP. A major complication of chemotherapy was acute kidney injury due to CDDP (26%). The 5-year OS and 5-year EFS were 64.9% and 57.1%, respectively. After 2006, a policy to prioritize the resection of the primary lesion was implemented, and if the primary lesion was deemed resectable, preoperative chemotherapy was either not administered or administered for only a short duration. The 5-year OS after 2006 improved to 78.8%. Conclusions This study shows that administration of high-dose intensity preoperative chemotherapy was difficult in middle-aged and older patients due to their high rate of acute kidney injury by CDDP. For cases of osteosarcoma in middle-aged and older patients, if the primary lesion is resectable, preoperative chemotherapy should be minimized to prioritize the resection of the primary lesion. It was considered that, with appropriate measures to prevent complications, adjuvant chemotherapy may lead to improved prognosis.
引用
收藏
页数:10
相关论文
共 6 条
  • [1] Definitive surgery of primary lesion should be prioritized over preoperative chemotherapy to treat high-grade osteosarcoma in patients aged 41–65 years
    Keiko Hayakawa
    Seiichi Matsumoto
    Keisuke Ae
    Taisuke Tanizawa
    Yuki Funauchi
    Yusuke Minami
    Masanori Saito
    Atsushi Okawa
    [J]. Journal of Orthopaedics and Traumatology, 2020, 21
  • [2] Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer
    Piedimonte, Sabrina
    Kessous, Roy
    Laskov, Ido
    Abitbol, Jeremie
    Kogan, Liron
    Yasmeen, Amber
    Salvador, Shannon
    Lau, Susie
    Gotlieb, Walter H.
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2020, 42 (11) : 1339 - 1345
  • [3] EURO-BOSS: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma
    Ferrari, Stefano
    Bielack, Stefan S.
    Smeland, Sigbjorn
    Longhi, Alessandra
    Egerer, Gerlinde
    Hall, Kirsten Sundby
    Donati, Davide
    Kevric, Matthias
    Brosjoe, Otte
    Comandone, Alessandro
    Werner, Mathias
    Monge, Odd
    Palmerini, Emanuela
    Berdel, Wolfgang E.
    Bjerkehagen, Bodil
    Paioli, Anna
    Lorenzen, Sylvie
    Eriksson, Mikael
    Gambarotti, Marco
    Tunn, Per-Ulf
    Jebsen, Nina L.
    Cesari, Marilena
    von Kalle, Thekla
    Ferraresi, Virginia
    Schwarz, Rudolf
    Bertulli, Rossella
    Kasparek, Anne-Katrin
    Grignani, Giovanni
    Krasniqi, Fatime
    Sorg, Benjamin
    Hecker-Nolting, Stefanie
    Picci, Piero
    Reichardt, Peter
    [J]. TUMORI JOURNAL, 2018, 104 (01): : 30 - 36
  • [4] Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma
    Tsuda, Y.
    Tsoi, K.
    Parry, M. C.
    Stevenson, J. D.
    Fujiwara, T.
    Sumathi, V
    Jeys, L. M.
    [J]. BONE & JOINT JOURNAL, 2020, 102B (06): : 795 - 803
  • [5] Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over
    Pitiyarachchi, Omali
    Ansell, Peter J.
    Coleman, Robert L.
    Dinh, Minh H.
    Holman, Laura
    Leath III, Charles A.
    Werner, Theresa
    Disilvestro, Paul
    Morgan, Mark
    Tew, William
    Lee, Christine
    Cunningham, Mary
    Newton, Meredith
    Edraki, Babak
    Lim, Peter
    Barlin, Joyce
    Spirtos, Nicola M.
    Tewari, Krishnansu S.
    Edelson, Mitchell
    Reid, Thomas
    Carlson, Jay
    Friedlander, Michael
    [J]. GYNECOLOGIC ONCOLOGY, 2024, 187 : 221 - 226
  • [6] NON-HODGKINS-LYMPHOMA IN ELDERLY PATIENTS - A PHASE-II STUDY OF MCOP CHEMOTHERAPY IN PATIENTS AGED 70 YEARS OR OVER WITH INTERMEDIATE-GRADE OR HIGH-GRADE HISTOLOGY
    BESSELL, EM
    COUTTS, A
    FLETCHER, J
    TOGHILL, PJ
    MOLONEY, AJ
    ELLIS, IO
    HULMAN, G
    JENKINS, D
    [J]. EUROPEAN JOURNAL OF CANCER, 1994, 30A (09) : 1337 - 1341